Morgan Stanley Maintains Equal-Weight on Bicycle Therapeutics, Lowers Price Target to $12

Morgan Stanley analyst Jeffrey Hung maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Equal-Weight and lowers the price target from $13 to $12.